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ABSTRACT 
Background For adult patients with type 2 diabetes mellitus and an Ale >7.0% despite 
maximal oral hypoglycemic therapy with metformin and a sulfonylurea, the relative benefits and 
harms oftriple therapy are unknown. In particular, it is unclear whether patients should 
commence insulin therapy, either alone or in combination with other agents, or whether desired 
glycemic control can be attained and maintained with other agents ( exenatide, alpha-glucosidase 
inhibitors, and/or thiazolidinediones). 
Objectives. To assess the efficacy-as measured by the change in AI c from baseline and 
by the proportion of patients attaining an Ale <7.0%; safety-as measured by the incidence of 
hypoglycemia and of treatment-related adverse events; treatment externalities-as measured by 
the effect on selected cardiovascular risk factors; and health outcomes-as measured by the 
effect on micro- or macro-vascular complications--of triple therapy. Economic considerations 
and effects on health-related quality oflife are also assessed. 
Methods. Eligible studies were identified by searching MEDLINE (1977-May 2007) with 
limits on subjects (humans), language (English), and publication (appearing in peer-reviewed 
literature). Inclusion criteria included, among others, that trials be randomized with both a 
minimum duration of follow-up (24 weeks) and an enrolled population (n=30); that at least one 
study arm investigate triple therapy; and that the authors report on key outcomes. Data extraction 
and assessment of study quality were undertaken by a single reviewer and made available for 
review. 
Results. Eleven randomized controlled trials, enrolling 3,306 participants with a median 
follow-up duration of24 weeks, were included. Overall, study methodologic quality was good. 
Trial participants were generally similar with respect to age, body mass index (BMI), duration of 
diabetes, and baseline Ale making it possible to generalize the results of this review to a likely 
externally valid population. 
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Ale lowering varied from 0.2%-1.8% and from least effective (alpha-glucosidase 
inhibitors) to most effective (thiazolidinediones and insulin glargine). Generalizing these 
averaged results to patients at differing levels of baseline glycemic control is limited. Irrespective 
of the third agent chosen, less than half of all trial participants attained Ale <7.0%, though this 
may reflect inclusion of participants with advanced disease. Nevertheless, results suggest 
reconsideration of glycemic targets as well as the possible inappropriateness of certain treatment 
recommendations. 
Third agents were generally safe and were well-tolerated. The incidence of serious 
adverse events was low (<3%) including severe hypoglycemia (1.5 events per 100 patient-years). 
Incidence of hypoglycemia appeared related to the sulfonylurea dose, suggesting a treatment 
recommendation, and to the ambient level of glycemic control, suggesting a shifting balance of 
benefits and harms with increasingly intensive therapy. The rarity of serious events precluded 
comparisons among particular agents. Treatment-related side effects, including their likelihood 
and severity, are discussed by drug class. 
Few of the trials reported on micro- or macro-vascular endpoints, economic 
considerations, or effects on health-related quality of life. The paucity of such data in the 
included literature has implications for future research. A hypothetical outcomes table is 
generated to facilitate discussion about the diminishing returns of additional treatment. 
Conclusions. The efficacy and safety of triple therapy in adults with type 2 diabetes 
mellitus has not been previously scrutinized in a systematic review. These results can supplement 
the existing body of knowledge and inform clinical practice. Further research is needed with 
regard to micro- and macro-vascular outcomes as well as a reconsideration of treatment goals in 
this population in light of such outcomes. This review further illustrates the validity and 
necessity of simiiar anaiyses being performed along the treatment continuum for patients with 
type 2 diabetes, to improve both patient-provider decision-making and utilization of health care 
system resources. 
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INTRODUCTION 
Two large-scale, randomized controlled trials (RCTs), the Diabetes Control and 
Complications Tria11•2 (DCCT) in patients with type 1 diabetes and the United Kingdom 
Prospective Diabetes Studl·4 (UKPDS) in patients with type 2 diabetes, have demonstrated 
signit!cant reductions in rates of microvascular compilcations in patients who improve glycemic 
control with intensive therapy versus conventional therapy. 
In the tJKPDS, patients receiving intensive treatment (mean A1c=7.0%) compared to 
those receiving conventional treatment (mean Alc=7.9%) benefited from a relative risk 
reduction over 10 years of 12% for any diabetes-related endpoint and 10% for any diabetes-
related death. However, aggregate measures were used and much of the reported risk reduction 
was due to an effect on microvascular endpoints. Furthermore, endpoints included intermediate 
outcomes such as need for retinal photocoagulation rather than health outcomes such as 
blindness. 
The long-term benefit of intensive glycemic control on macrovascular outcomes in type 1 
•• • • • • • -<:;f'i,..,......, •• • ·• • • 7 • • • ,.. ·· diabetes has also been shown.-·- W hlle observatiOnal data· and a meta-analysis ot prospective 
cohort studies8 support a similar benefit in type 2 diabetes, no RCT to date has shown such an 
etlect. 
Several professional societies have issued guidelines on glycemic control for patients 
with type 2 diabetes. Presently, the American Diabetes Association (ADA) recommends a 
glycated hemoglobin level (HbAlc or Ale) less than 7.0% for most patients,9 while the 
American Academy of Cilmcai Endocrinologists (AACE) and the European Association tor the 
Study of Diabetes (EASD) both recommend an Ale less than 6.5%. One systematic review10 and 
an editorial11 argue that setting uniform targets for Ale for all patients is inappropriate. To treat 
unwaveringly toward an Ale less than 7.0% is potentially harmful both for patients11•12 and for 
I. 13 14 po 1cy. ' 
The artificiality in treatment goals should not obscure the important benefits of any 
reduction in Ale. While no threshold effect in terms of tight glycemic control and 
microvascular-and perhaps macrovascular-complication risk reduction has been observed, 15 
the incremental absolute benefits of intensive therapy decrease at lower Ale levels and these 
smaller benefits must be weighed against harms of increased risk of hypoglycemia, weight gain, 
and the cost of multiple drugs, among others. 
NHANES 1999-2000 data suggests that only 37.0% of participants maintain an Ale less 
than 7.0% and 37.2% of participants are above the recommended "take action" Ale of greater 
than 8.0%. 16 Indeed, population-based glycemic control has not improved substantially in the 
past decade, with the prevalence of patients whose Ale values exceed 8.0% remaining 
stubbornly constant. 17•18 In the UKPDS, fewer than 30% of patients were able to achieve AI c 
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levels less than 7.0% on monotherapy19 and more than half of all patients ultimately required the 
addition of insulin?0 The decade between 1990 and 2000 was marked by an increase in the use 
of oral antidiabetic drugs in combination with each other, from <1% to 29%, and with insulin, 
from 4% to 9%.21 
The need for progressive therapy reflects the underlying pathophysiologic defect in type 
2 diabetes-progressive pancreatic beta-cell dysfunction and increasing peripheral resistance to 
insulin. Reported failure rates for single oral agents of 5% to 20% per year mean that single oral 
therapy in type 2 diabetes seldom maintains glycemic control more than three years. Optimizing 
treatment decisions to reduce complications and spare remaining pancreatic endocrine function 
becomes of paramount importance. 
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Treatment inertia remains the norm in the United States (US). In one managed care study, 
for example, patients received only monotherapy despite 14-20 months of exposure to Ale levels 
greater than 8.0% until a second oral agent was added.22 Because the introduction of dual-agent 
therapy has the potential to lower Al c levels by only an additionall.2%-2.0%, use of a third oral 
agent, whether another oral drug or insulin, is invariably required in many patients with 
advancing type 2 diabetes. 15·23 
Several barriers prevent better glycemic control, including sub-optimal decision making. 
The decision to add therapies, including insulin, in patients inadequately controlled on 
monotherapy or dual oral therapy may often be delayed by the patient or by the provider. In the 
case of insulin, several reasons have been advanced including physician resistance to prescribing, 
patient reluctance, or the perception that insulin therapy implies severe disease, among 
h 24 25 Whil . I b . . 1· h 1' . b t ot ers. · e conventwna arners to msu m t erapy- mgenng concerns a ou 
hypoglycemia, complex regimens, and erratic absorptions-have been substantially overcome 
with the advent of insulin analogues, fear of hypoglycemia and injections remain a real 
obstacle.26.27 As a result, triple oral therapy appears a valid therapeutic step, appealing for many 
patients. 
The introduction of new classes of blood-glucose lowering medications to supplement 
more established therapies-lifestyle interventions, insulin, sulfonylureas, and metformin-has 
increased the treatment options for type 2 diabetes. In addition, provider and patient uncertainty 
regarding the most appropriate way to proceed has increased. Despite the introduction of these 
new classes of medication for managing type 2 diabetes, recent studies suggest even currently 
available multi-drug therapies often do not allow patients to achieve better glycemic control.28•29 
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The ADA and EASD recently released a consensus algorithm to guide disease 
management.30 The algorithm highlights both the tendency to treat toward an Ale level-or, to 
define any level above 7.0% as inadequate or suboptimal control-and the range of options for 
achieving the target goal. The uncertainty alluded to above is highly prevalent in an increasingly 
common clinical scenario: an adult patient with poorly controlled type 2 diabetes mellitus 
already on two oral agents (metformin plus a sulfonylurea) facing a choice among adding a third 
oral agent, initiating insulin, or taking no action. 
While this choice is highly driven by patient and provider preferences and therefore 
amenable to shared decision-making, augmented by a decision aid, this choice and the 
subsequent creation of a decision aid benefit first from a systematic review of the existing 
literature regarding the incremental benefits and harms of the range of possible therapeutic 
agents. 
METHODS 
Key question. For adults (> 19 years of age inclusive) with type 2 diabetes mellitus and an 
Ale >7.0% already on two oral agents (metformin plus a sulfonylurea), what are the benefits-in 
terms of glycemic control and of prevention of micro- and macro-vascular outcomes-and 
harms-in terms of treatment-related adverse events or intolerance due to side effects-of 
available add-on therapeutics including and compared to insulin? 
Databases and Search Terms. To develop an appropriate search strategy, including which 
databases to search and which terms to input into search fields, a medical librarian with expertise 
in information retrieval was consulted and available during all phases of the review. 
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The author performed an electronic literature search ofMEDLINE (1977 through May 
2007) using the search strategy detailed in Table I. Briefly, pilot testing was performed on a 
simplistic search strategy using the MeSH terms "Diabetes mellitus, type 2" and "hypoglycemic 
agents." It was determined that, notwithstanding reasonable contraindications, metformin and a 
sulfonylurea was sufficiently common in studies of dual oral therapy that they be included in 
each subsequent search string as keywords. While "hypoglycemic agents" and "sulfonylurea 
compounds" lead to duplication, cataloging of studies including a sulfonylurea in dual oral 
therapy seem indexed by the latter term with newer studies by the former. Thus, both terms were 
included parenthetically in the search string with the Boolean operator "OR." 
This combination of keywords and MeSH terms were then appended to each possible 
permutation of the following keywords: exenatide (as a keyword rather than a substance name), 
acarbose or miglitol (alpha-glucosidase inhibitors), rosiglitazone or pioglitazone 
(thiazolidinediones), and insulin (again as a keyword). To ensure capture of articles in which 
insulin was part of the therapeutic regimen, an additional search was performed using the 
following MeSH terms: "diabetes mellitus, type 2" AND "hypoglycemic agents" AND "drug 
therapy, combination." This search was also used as a rudimentary sensitivity analysis for the 
preceding searches. The search was restricted to English-language studies, conducted in human 
subjects, and appearing in the published literature. 
The author also performed hand-searches of all bibliographies of articles returned that 
were retained on the basis of abstract as well as bibliographies of contemporaneous reviews 
returned by the search strategy. The number of trials returned by each search query, the number 
of articles initially included and excluded after abstract review, the number of articles added after 
hand-searching of relevant bibliographies, the number of articles retained for full review, and the 
number of articles rejected after full review or included in the systematic review are detailed in 
Table 2. 
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Pilot searching also included targeted keyword searches for articles concerning newer 
agents like pramlintide (an amylin analog), sitagliptin and vildagliptin (DPP-IV inhibitors), 
liraglutide (an oral GLP-1 receptor agonist), and repaglinide and nateglinide (meglitinides, rapid-
acting non-sulfonylurea insulin secretagogues ). While evidence about these agents as 
monotherapy and in combination therapy is certainly useful to guide clinical practice, it was felt 
that the body of evidence for these agents in triple therapy was insufficient to warrant inclusion 
at this time. In the case of the glinides, studies have shown no further antihyperglycemic effect 
when added to a sulfonylurea.31 
Article Selection and Review. The author evaluated all titles, abstracts, and keywords of 
every record retrieved for inclusion or exclusion. Full articles were retrieved for further 
assessment if the information given suggested that the study included patients with type 2 
diabetes, used random allocation to comparison groups, included an arm oftriple therapy, and 
assessed one or more relevant clinical outcome measures for both efficacy and safety. If there 
was any doubt regarding inclusion of the article from the information given in the title and 
abstract or if no abstract was available, the full article was retrieved for clarification. The list of 
included and excluded articles was made available for review. Differences of opinion were 
resolved by consensus. 
Inclusion and Exclusion Criteria. Guided by the focused clinical question, the author 
generated inclusion and exclusion criteria summarized in Table 3. 
Types of participants: Adult patients (> 19 years of age inclusive) with type 2 diabetes 
mellitus (according to appropriate diagnostic criteria at the time of the study) of any duration 
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(other than newly diagnosed) who had not achieved satisfactory glycemic control on an existing 
stable regimen ofmetformin (maximally tolerated) and a sulfonylurea (at least half maximal 
dosing) prior to randomization were included. Any doses of any agent inconsistent with 
reasonable clinical practice were explained; any adjustments to dosages during the trial likewise 
needed to be explicit. Exclusion criteria included patients with type 1 diabetes mellitus, diabetes 
of secondary cause ( eg, hemochromatosis), gestational diabetes, pre-diabetes/ impaired glucose 
tolerance/ impaired fasting glucose, or metabolic syndrome. Any studies occurring in the 
pediatric and/or adolescent patient populations ( <18 years of age inclusive) were excluded. 
Types of study settings: Any study conducted in the outpatient population or an otherwise 
ambulatory care setting, given that this is the setting in which the information is most applicable 
and the setting in which pilot testing of any decision aid would occur, were included. Exclusion 
criteria included studies conducted in or regarding inpatient, hospital, or intensive short-term 
management. 
Types of study designs: Randomized controlled trials with follow-up periods of at least 
24 weeks and an evaluable total study population of at least thirty participants were included. 
The guideline regarding number of participants in the final analysis was included because of the 
statistical difficulties associated with small sample sizes. At least one trial arm must include the 
investigation of an add-on third agent to existing dual oral therapy with metformin and a 
sulfonylurea. Other trial arms may include a placebo or an active comparator which need not also 
be "triple therapy." Exclusion criteria included any non-randomized trial (prospective or 
retrospective cohort, case-control, case-series). 
Types of outcomes: In order to be included, trials had to report both main outcome 
measures--change in HbA 1 c from baseline (placebo-subtracted or otherwise) AND measures of 
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treatment-related adverse events or side effects. Adverse events could include incidence of 
hypoglycemia and weight gain, as well as other side effects specific to particular agents. 
Additional outcome measures which were not used as a basis for inclusion or exclusion but 
abstracted for reporting included other measures of glucose status (fasting plasma glucose, 
postprandial glucose), proportions attaining recommended Ale levels, cost-effectiveness data, 
any quality-of-life data reported using a validated instrument, and any diabetes-related morbidity 
or mortality. 
In terms of general limitations, most were included because of logistical issues with the 
resources available to the systematic review and to the author. Because only published studies 
were included, the author acknowledges the potential publication bias created and the resultant 
tendency for studies to overestimate the efficacy of agents. 
Quality assessment. Each trial was assessed by the author using a selection of the 17-item 
Maastricht-Amsterdam Criteria List,32 which includes criteria from previous work.33•34 The 
following factors were scored (total score range from 0-7): 
1. Minimization of selection bias- a) was the randomization procedure adequate? b) was 
the allocation concealment adequate? 
2. Minimization of performance bias- were a) the patients and b) the people administering 
the treatment blind to the intervention? 
3. Minimization of attrition bias- a) were withdrawals and dropouts completely described? 
b) was analysis by intention-to-treat? 
4. Minimization of detection bias- were a) outcome assessors blind to the intervention? 
Based on these criteria, studies were subdivided into four categories: Excellent (total 
score 6-7): all quality criteria met: low risk of bias; Good (total score 4-5): one or more of the 
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quality criteria only partly met: moderate risk of bias; Fair (total score 2-3): one or more of 
the quality criteria not met: high risk of bias; Poor (total score 0-1): nearly all of the criteria 
not met: severe risk of bias. Studies were not excluded on the basis of methodological criteria. 
External validity was scored dichotomously; that is, either as likely valid or likely not valid 
to the proposed external population. 
Data extraction. Data regarding inclusion criteria, quality criteria, and results were 
extracted solely by the author. The following information was collected: 
1. General information: title, authors, reference, PMID. 
2. Trial characteristics: design, duration, randomization (and method), allocation 
concealment (and method), blinding (patients, people administering treatment, 
outcome assessors), assessment of blinding; run-in period and lifestyle counseling or 
dietary reinforcement. 
3. Intervention(s): Placebo or active comparator, add-on agent (dose, route timing), 
existing regimen of metformin and sulfonylurea (dose, route, timing), and protocol 
specifying adjustments to both. 
4. Patients: sampling (method), exclusion criteria, the total number of participants and 
the number randomized in each comparison group, as well as intention-to-treat (ITT) 
population for safety analysis and the evaluable population (per protocol population) 
for efficacy analysis. Patient characteristics including age, BMI, and duration of type 
2 diabetes. 
5. Outcomes: Changes in HbA1c from baseline changes from baseline and proportions 
of the study population experiencing drug-related adverse events and/or side effects-
particularly hypoglycemia and effect on weight; other measures of glucose control 
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including, but not limited to, fasting plasma glucose, postprandial glucose, and 
proportion of subjects treated achieving Ale <7.0%; risk reduction of microvascular 
or macrovascular complications 
6. Results: whether or not a power calculation was performed and whether the analysis 
included adjustments including, but not limited to, intention-to-treat and last 
observation carried forward. 
RESULTS 
Efficacy. The change in Ale from baseline was the primary outcome measure for efficacy. 
All trials, per inclusion criteria, reported on this endpoint. Taken collectively, add-on agents, in 
addition to existing metformin and sulfonylurea therapy, lowered Al c by 0.2-1.8%. Alpha-
glucosidase inhibitors, acarbose and miglitol, were the least effective drug class achieving 
modest reductions in Ale of approximately 0.5%. Thiazolidinediones, pioglitazone and 
rosiglitazone, and triple therapy regimens containing insulin glargine were the most effective, 
lowering Ale by 0.9-1.8%. 
The proportion of patients attaining an Ale< 7.0% was a secondary outcome measure for 
efficacy. Eight of eleven trials (8/11, 72.7%) reported on this endpoint. In none of the eleven trial 
arms considered (excluding placebo and non-triple therapy comparators) did the proportion 
exceed 50%. Proportions were comparable irrespective of the add-on agent and ranged from 
24%-49%. 
Safety. Hypoglycemia was one of the principal outcome measures for safety. 
Hypoglycemia was reported either as a proportion or as a rate in all but one study (10/11, 90.9%). 
In terms of overall hypoglycemia, proportions ranged from 28%-53% and rates from 2.7-7.7 
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events per patient-year. Trials generally categorized hypoglycemic events either as mild-
moderate (subjects reported symptoms consistent with hypoglycemia and may have documented 
levels of plasma glucose <70mg/dl) or as severe (requiring the assistance of another person to 
obtain treatment, including intravenous glucose or intramuscular glucagon). Definitions were 
similar across all studies. Because of the rarity of the event, a comparison of the incidence of 
severe hypoglycemia across treatment groups was not made. The overall incidence rate of severe 
hypoglycemia, calculated from 68,064 patient-weeks of follow-up among the ten trials reporting, 
was 1.5 events per 100 patient-years. 
Drug-related adverse events, specific to particular agents or to a drug class, were a second 
principal outcome measure for safety. In general, all third agents were safe and well-tolerated. 
The incidence of severe events was low ( <3%) irrespective of agent and this finding was robust. 
Less than half of severe adverse events were deemed-treatement related and few led to 
participant withdrawal from the trial. Particular agent specific effects, their incidence and their 
management, are discussed further by drug class. 
Treatment externalities. While glycemic control remains the cornerstone of therapy in 
type 2 diabetes, increasing importance is placed on proper management and amelioration of other 
cardiovascular risk factors: weight, blood pressure, lipid profile, and tobacco status. All but one 
trial (10/11, 90.9%) reported on the effect of a third agent on weight. Exenatide was associated 
with weight loss of 1.6-2.5kg. This effect was independent of glycemic effect and treatment-
related gastrointestinal side effects. Acarbose and miglitol were associated with modest weight 
reductions of 0.3-0.Skg, though these drugs are generally regarded as weight neutral. The 
thiazolidinediones and regimens containing insulin were both associated with weight gain, from 
3.0-3.5kg and from 1.8-2.9kg, respectively. 
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Six of eleven trials (54.5%) reported on the effect on lipid profile but few of these 
reached statistical significance. In general, neither exenatide nor the alpha-glucosidase inhibitors 
had a significant effect on lipid profile, likely related to their respective underlying mechanisms 
of action. Rosiglitazone had unfavorable effects on lipids (increased total cholesterol (TC), low 
density lipoprotein (LDL), and triglycerides (TG)) while insulin glargine had favorable effects 
on lipids (decreased TC, LDL, and TG; increased high density lipoprotein (HDL)). None ofthe 
trials reported on blood pressure; trials which commented on a possible favorable effect were 
difficult to interpret in light of the significant number of trial participants receiving concomitant 
antihypertensives. 
Health outcomes. Only 1/13 (7.7%) trials reported on micro- or macro-vascular endpoints. 
The UKPDS was the only trial in which measurement of these endpoints was included in the 
protocol and the only trial with a sufficient duration of follow-up to capture these events. The 
UKPDS reported data concerning "any diabetes-related endpoint" and microvascular disease. 
The relative risks for acarbose compared with placebo were 1.00 (95% CI 0.81-1.23) and 0.91 
(95% CI 0.61-1.35), respectively. Interpretation of this and other measures in this trial were 
complicated by the high overall loss to follow-up (56.9%). 
Few trials (2/13, 15.4%) reported cost considerations. In one trial the authors found a 
significant difference in cost of care between insulin plus metformin ($3.20/day) and triple 
therapy ($10.40/day) despite similar effects on Alc.61 In another trial, the authors estimated the 
total mean cost of glycemic control over 24 weeks to be $235 lower among subjects treated with 
insulin glargine ($1,368) compared with subjects treated with rosiglitazone ($1,603).60 
Similarly few (3/13, 23.1 %) trials reported on health related quality-of-life using 
validated instruments (two trials reported their results elsewhere). In each case, comparisons 
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were primarily to gauge quality of life with either exenatide, a glitazone, or insulin mono therapy 
compared to a triple therapy regimen containing basal insulin. Few differences were found in 
h . . . d h I' . I I . f h fi d' . nkn 46 79 so eac pmrw1se comparison an t e c mica re evance IS o sue m mgs IS u own. · · 
Characteristics of included studies. 49 studies were retained for full review of which II 
are included in this review. Excluded studies tended to be of insufficient sample size or duration, 
were nonrandomized, or did not include a triple therapy treatment arm. The studies that were 
included had good internal validity. The population to whom these results are externally valid are 
best described as a middle-aged to elderly population, overweight, with a relatively long duration 
of diabetes, and a baseline Ale above 8.0%, already on metformin and a sulfonylurea .. 
SUPPLEMENTARY RESULTS AND DISCUSSION BY AGENT OR DRUG CLASS 
Exenatide. Three articles fulfilled inclusion criteria. Study designs were similar. Patients 
continued maximally tolerated metformin plus a sulfonylurea and were randomized either to 
exenatide or placebo,35 to exenatide or insulin glargine,36 or to exenatide or insulin aspart.37 
Study populations were similar with respect to age, body mass index (BMI), duration of diabetes, 
and baseline Ale. Withdrawal rates were differential in two trials: 19.4% (exenatide) versus 
9.7% (insulin glargine), 9.5% (exenatide) versus 0.7% (insulin glargine) due to adverse events36; 
21.3% (exenatide) versus 10.1% (biphasic insulin), 7.9% (exenatide) versus 0.0% (biphasic 
insulin) due to adverse events.37 
Exenatide, as an add-on to existing metformin and sulfonylurea therapy, lowered Ale by 
0.8-1.1% from baseline, superior to placebo and non-inferior to either insulin regimen tested. 
Exenatide demonstrated comparable efficacy in two parallel phase III RCTs, one in which 
exenatide was added to sulfonylurea monotherapy,38 the other in which it was added to 
metformin monotherapy.39 46 patients in a phase II study already on and continuing metformin 
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and sulfonylurea therapy also experienced Ale lowering.40 However, this study was not designed 
to assess differences among various treatment groups. 
Change in AI c over time shows the greatest reduction in AI c occurs at 12-16 weeks 
post-initiation and decreases slightly thereafter.35' 39 Improvements in glycemic control have been 
sustained up to 82 weeks in open-label extensions41 '42•43 of the phase III RCTs. Additional gains 
in A 1 c reduction seem likely attributable to the dose escalation of all patients to the 1 Oug twice 
daily dose at the start of the open-label extensions. 
From one-third to nearly one-half of exenatide-treated patients attained Ale levels less 
than 7%.35' 37 Again, the pivotal phase III trials38•39 observed similar proportions as did their 
open-label extensions.4143 Limitations to the latter analysis include the lack of a comparator 
group and self-selection bias, though the authors attempted to control for both in their analyses. 
Weight loss of 1.6-2.5kg was an important treatment externality. Weight loss was 
statistically significant as early as two weeks post-initiation of exenatide treatrnent.36•37 Weight 
loss was similar when exenatide was added either to sulfonylurea or to metformin 
monotherapy.38•39 Reduction in body weight was progressive in three 82-week completer cohorts, 
with losses of 4.0-5.3kg.4H 3 
Beneficial changes in lipid profiles and in blood pressure were noted in the open-label 
trials but not in their randomized predecessors. Additional trials controlling for these factors are 
needed. 
The most common adverse events were gastrointestinal, including nausea (33.0-57.1%), 
vomiting (13. 7-17.4% ), and diarrhea (8.5-17 .4% ).35 ' 37 All side effects appear dose-dependent44 
and gradual dose escalation has been shown to attenuate these effects.45 Incidence of treatment-
emergent nausea was generally of mild-to-moderate intensity and peaked during the initial weeks 
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of dosing then decreased thereafter.35.39 Studies generally included a post hoc analysis of weight 
change stratified by whether or not the patient had experienced nausea, in addition to calculating 
a Pearson's correlation coefficient. Gastrointestinal side effects were not a significant cause of 
the weight reduction observed in patients receiving exenatide. 
Hypoglycemic events were reported both as a proportion35 (27.8%) and as a rate36•37 (4.7-
7.3 events per patient-year). One trial's study design35 enabled an assessment of the influence of 
concurrent sulfonylurea dosing on risk of hypoglycemia. The overall incidence of hypoglycemia 
was lower among those patients randomized to the minimum recommended dose of sulfonylurea 
compared to those randomized to the maximally effective dose with small attenuation of the 
effects on glycemic control. 
The increased hypoglycemia observed is likely a composite of background sulfonylurea 
susceptibility and superimposed exenatide effect. This conjecture is supported by low rates of 
hypoglycemia in the exenatide plus metformin monotherapy trial39 compared with the others in 
which a sulfonylurea was part of the treatment regimen.35-38 A proactive approach to sulfonylurea 
dose reduction will likely limit the incidence of hypoglycemia in exenatide-treated patients. For 
example, 33% (84/253) of exenatide-treated patients had their sulfonylurea dose reduced with 
resultant decrease in rates of hypoglycemia but without attendant compromise of reductions in 
Alc.37 
Anti-exenatide antibodies were detected in 43-49% of patients by study's end in each of 
the three trials and were generally oflow titer.35-37 The presence or absence of antibodies had no 
predictive effect on the magnitude of an individual's glycemic response or on the incidence of 
adverse events. The clinical significance of the development of antibodies is unknown at this 
time. 
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None of the trials reported on micro- or macro-vascular endpoints, cost data, or health-
related quality oflife (HRQOL). One trial36 used validated instruments to measure quality-of-life 
but results are reported elsewhere.46 In the per protocol population (n=455), both exenatide and 
insulin glargine were associated with significant improvements in patient-reported outcomes. 
The negatives of an additional daily injection and a higher rate of gastrointestinal adverse events 
were likely balanced by the positives of weight loss in patients treated with exenatide. Whether 
these gains in patient satisfaction are clinically meaningful in terms of adherence is not known. 
Two cost-effectiveness analyses have also been reported elsewhere.47•48 Although 
exenatide was generally associated with an increase in direct medical costs, the gains in quality-
adjusted life years (QALYs) translated into mean incremental cost-effectiveness ratios (ICERs) 
commonly regarded as cost effective. 
Acarbose and miglitol. Three articles fulfilled inclusion criteria. Study designs were 
similar in two. Patients continued metformin plus a sulfonylurea and were randomized either to 
acarbose or placebo49 or to miglitol or placebo.50 The third study was embedded within the larger 
UKPDS trial. 51 Randomization was not stratified according to preexisting therapy, so imbalances 
may exist between the acarbose and placebo treatment arms within any given preexisting therapy 
group (i.e., metformin plus sulfonylurea). However, analyses are performed and results are 
reported in such a way as to permit a comparison. Biases due to inter-group variability are likely 
greater than intra-group variability, randomization appears successful, and selection bias is 
minimal. 
Study populations were similar in two.50•51 One study population differs from the other 
two trials most importantly in terms of mean BMI: 24.8 (acarbose/9 versus 27.7 (acarbose)50 and 
29.8 (acarbose).51 This study population is also internally homogeneous with respect to 
20 
demographics; standard deviations are small.49 Withdrawal rates were nondifferential in all trials. 
56.9% overall loss to follow-up within the metformin plus sulfonylurea treatment group was 
observed in the UKPDS trial; analyses were performed by allocated therapy (intention-to-treat) 
and by actual therapy. 51 
Acarbose or miglitol, as an add-on to existing metformin and sulfonylurea therapy, 
lowered Ale by 0.5-0.55% from baseline at 24 weeks, and 0.20% (allocated therapy) or 0.32% 
(actual therapy) from baseline at 3 years. Neither of these latter differences was statistically 
significant. A greater initial reduction in median A 1 c was observed in the UKPDS trial though it 
did not achieve statistical significance; thereafter, AI c levels rose steadily to the three-year end-
point. None of the included trials reported the proportion of acarbose-treated patients attaining 
Ale levels less than 7%. One trial divided acarbose-treated patients into responders (reduction in 
Ale >0.5%) and non-responders (reduction in Ale <0.5%); no significant predictors of treatment 
effect were found. 
A critical review of acarbose52 and a Cochrane meta-analysis53 of published, placebo-
controlled studies in which an alpha-glucosidase inhibitor was studied either as monotherapy or 
combination therapy found comparable reductions in Ale (0.68-0.77%). The latter study found a 
larger effect on Ale for patients with higher baseline Ale 
(-0.12% decrease for every +1.0% baseline Ale) and an inverse relationship with study duration 
(the less effect on Ale the longer the follow-up period).53 
Smaller prospective trials where acarbose was added to metformin plus a sulfonylurea 
have yielded conflicting results. In one placebo-controlled study (n=28), no significant 
improvements in A 1 c levels after four months were detected in patients randomized to acarbose; 
however, a relatively low-dose (150mg/d) of acarbose was used. 54 Two open label studies, one in 
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Thai1and55 (n=36) and the other in the US56 (n= 11), found significant differences in Ale from 
baseline; however, both studies also found significant decreases in body weight, not usually 
associated with acarbose therapy. Positive results of the magnitude reported in these studies (1.0-
1.4%) are likely attributable as much to dietary reinforcement as to acarbose. In the latter trial, 
the high baseline Ale of enrolled subjects (13.6%) also calls into question whether or not 
patients were fully optimized on existing therapy. Another study in which placebo or acarbose 
were compared to bedtime NPH insulin 57 (n=29) found decreases in AI c of 0.8% when acarbose 
was added to failing metformin-sulfonylurea therapy. 
Modest weight loss of 0.3-0.54kg was reported in two trials.49•51 Differences in the 
Chinese diet coupled with dietary reinforcement during the run-in phase probably explains the 
former study consistent with results reported elsewhere. 58 Overall, acarbose and miglitol are 
generally regarded as weight neutral. No significant differences in hypoglycemic events or in 
lipid profiles were observed in any of the trials. 
The most common adverse events were gastrointestinal, including flatulence (30.0-
62.2%), diarrhea (11.0-16.0%), and abdominal pain (1.0-4.0%).49. 51 The occurrence of side 
effects appears to be dose dependent and gradual dose escalation may attenuate these effects 
somewhat. In the UKPDS trial, side effects were often the reason given for noncompliance: 
flatulence (30%) and diarrhea (16%). The authors note that most of the patients who 
discontinued acarbose therapy did so during the first year, suggesting that once tolerance is 
established, adherence is easier to maintain. 51 
None of the trials reported on cost data or on health-related quality oflife (HRQOL). The 
UKPDS reported data concerning "any-diabetes related endpoint" and microvascular disease. 
The relative risks for acarbose compared with placebo were 1.00 (95% CI 0.81-1.23) and 0.91 
(95% CI 0.61-1.35), respectively. 51 
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Though improvements in glycemic control are comparatively modest, alpha-glucosidase 
inhibitors' place in diabetic pharmacotherapy must be considered given their weight and 
hypoglycemic "neutrality" as well as their effects on postprandial glucose levels and non-
dependence on residual beta-cell function. 
Rosiglitazone and pioglitazone. Three articles fulfilled inclusion criteria. Study designs 
were similar. Patients continued metformin plus a sulfonylurea and were randomized either to 
rosiglitazone or placebo, 59 to rosiglitazone or insulin glargine/0 or to a glitazone (rosiglitazone 
or pioglitazone) or premixed insulin (continuing only metformin).61 Study populations were 
similar with respect to age, body mass index (BMI), and duration of diabetes. The mean baseline 
Ale was higher in one trial, owing to the exclusion criteria of those with an Ale less than 
8.0%61 Withdrawal rates were differential in one study (19.9% (rosiglitazone) versus 37.0% 
(placebo), 67.6% of the latter figure owing to hyperglycemia or loss of glycemic control). 59 
Rosiglitazone or pioglitazone, as an add-on to existing metformin and sulfonylurea 
therapy, lowered AI c by 0.9-1. 77% from baseline, superior to placebo and non-inferior to either 
insulin regimen (though neither trial was set-up to demonstrate non-inferiority). A planned 
subgroup analysis in one study found that when baseline Ale exceeded 9.5%, the reduction in 
Ale with insulin glargine was significantly greater than with rosiglitazone, suggesting adding a 
glitazone may be beneficial when baseline A 1 c is modestly elevated, but inappropriate at higher 
levels.60 
One study design permitted treatment switches: patients failing three oral drugs, rather 
than being withdrawn, were transferred to insulinlmetformin therapy, or if on insulin plus 
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metformin, were switched to a multiple-injection regimenYI3.3% (13/98) of patients on triple 
oral therapy were switched to metforminlinsulin by study's end (Ale mean (SD) pre-switch 9.85 
(1.70); post-switch 8.06 (1.36). 2.4% (2/90) of patients on insulin were switched to basal-bolus 
therapy by study's end; both patients experienced slight increases in Ale. 
The efficacy of rosiglitazone or pioglitazone, as an add-on to metformin plus a 
sulfonylurea, has been demonstrated elsewhere and corroborates the findings above. 
Rosiglitazone was added to existing therapy, including metformin plus a sulfonylurea (n=4247), 
in a large six-month observational study in Germany. The triple therapy treatment group 
experienced a 1.3% reduction in Ale with 48.0% achieving an Ale <7.0%, despite a higher 
baseline A I c, BMI, and longer duration of diabetes. 62 Several smaller prospective trials 
involving rosiglitazone have reported similar results: an AI c reduction of 1.8% in a minority 
population (n=48),63 0.97% at a lower dose (4mg/d) and in a reasonably well-controlled 
population (mean (SD) baseline Ale 7.54 (0.9)) (n=30),64 and 1.1% in a population of Greek 
diabetic patients (n=38).65 
Pioglitazone lowered Ale by 1.5% with 61% of patients achieving Ale levels <6.5% in 
an aggressive treat-to-target prospective open-label study (n=54)66 and a retrospective cohort 
conducted by chart review (n=45) with comparison to a previous studl3 found pioglitazone 
lowered Ale by 2.1%.67 
Rosiglitazone and pioglitazone have also been compared to various insulin regimens in 
several smaller prospective trials. Reductions in Ale have again been similar: 1.8% 
(rosiglitazone) versus 1.5% (insulin glargine) (n=20)68 ; 0.9% (rosiglitazone) versus 1.2% 
(premixed (70/30) insulin with evening meal) (n=l7)69; 1.9% (pioglitazone) versus 2.3% (NPH 
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insulin qhs) (n~62).70 This latter trial was randomized but was excluded for insufficient follow-
up (16 weeks). 
Weight gain of3.0-3.5kg was reported in all three trials.59.61 This weight gain does not 
seem to blunt reductions in glycemic control and is largely independent of the fluid retention 
well-known to this drug class. Effect on lipids was reported in all three trials; effect was either 
non-significant or effects favored the insulin-included regimen. However, of the three trials, all 
but one involved rosiglitazone and this remaining study involved 50% of patients on each 
agent.61 A well-done randomized triaC1 and a retrospective cohort conducted by chart review72 
focused on comparing the two members of the TZD drug class and their respective effects on 
lipid profiles. Overall, pioglitazone has demonstrated more favorable effects (greater increases in 
HDL, more modest increases in LDL, and decreases in TGs) than has rosiglitazone. 
Hypoglycemic events were reported both as a proportion59•60 (48.0-53.0%) and as a rate61 
(3.4 events per patient-year). Incidence has generally been lower and of greater variation in other 
reported studies (0.0-37.0%)64' 66•70, though studies also vary widely in their definition of and 
recording of hypoglycemic events. In both trials in which an insulin-containing regimen was 
used as an active comparator, the incidence of hypoglycemia in the TZD-containing regimen was 
significantly less. One trial did not report adverse events other than those related to 
hypoglycemia.61 Otherwise, the most common significant adverse event was mild to moderate 
edema (8.0-12.5%), a side effect well-known to this drug class. Incidence has been of greater 
variation in other reported studies (0. 78-19% ). 62' 67•70 The liver toxicity which led to the market 
recall of troglitazone, the first member of this drug class, has not been appreciable outside of rare 
case reports with either of these agents. 
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None of the trials reported on micro- or macro-vascular endpoints. A recently published 
meta-analysis of randomized trials has caused both alarm in the health-care community and 
criticism of the Food and Drug Administration (FDA).73 The meta-analysis found in those 
patients taking rosiglitazone compared with controls, the odds ratio for myocardial infarction 
was 1.43 (95% CI, 1.03-1.98, p=0.03) and the odds ratio for death from cardiovascular causes 
was 1.64 (95% CI, 0.98-2.74, p=0.06). Limitations of the analysis include lack of a time-to-event 
analysis and the fact the analysis pools trials not designed to investigate the outcomes of interest 
(e.g., myocardial infarction and death from cardiovascular causes). Because the event is 
relatively rare, confidence intervals are wide and differential misclassification could bias the 
results. The largest trials, which are included in the analysis, yield somewhat conflicting 
information.74•75 The population in the former trial differs importantly from the population 
addressed herein, dealing with primary prevention in patients with impaired glucose tolerance. 
Given the effect of rosiglitazone on lipids and on edema in the setting of susceptibility to 
congestive heart failure, 76 a biologically plausible mechanism exists for the effect seen; the 
ongoing Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in 
Diabetes (RECORD) trial may provide further support or refutation.77 It is important to note that 
pioglitazone, with its more favorable effect on lipids, has shown a trend toward benefits in terms 
of a composite end-point representing coronary and peripheral vascular events (hazard ratio, 0.90, 
p=0.095) and a secondary endpoint consisting of myocardial infarction, stroke, and death from 
any cause (hazard ratio, 0.84, p=0.027).78 However, no similar pooled analysis has been 
undertaken; thus what effect may exist cannot yet be said to represent a "class effect." 
Two of the trials reported on cost data; in both cases, cost of care analysis demonstrated 
superiority for the insulin-included regimen. None of the trials reported on health-related quality 
of life. One trial60 used validated instruments to measure quality-of-life but results are reported 
elsewhere. 79 This study found both rosiglitazone and insulin glargine groups showed 
improvements in HRQOL, although subjects treated with insulin glargine experienced 
significantly greater improvements in several dimensions, notably total symptom score and 
overall perception of general health. 
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Insulin. Two articles fulfilled inclusion criteria, in addition to those studies already a part 
of the review that included a "triple therapy with insulin" arm. Concerning the two additional 
trials, study designs were similar. Patients continued maximally tolerated metformin plus a 
sulfonylurea and were randomized either to a bedtime dose ofNPH insulin80 or to a morning 
dose of insulin glargine.81 In both trials, the comparison arm was premixed insulin (70% 
NPH/30% regular) dosed twice daily as monotherapy. Neither trial included a placebo arm, 
therefore differences are from baseline as opposed to placebo-subtracted from baseline. 
Study populations were similar with respect to age, body mass index (BMI), duration of 
diabetes, and baseline Ale. Patients randomized to premixed insulin had a significantly lower 
BMI (mean (SD) = 28.5 (3.8)) than patients randomized to bedtime NPH plus oral hypoglycemic 
agents (OHAs) (mean (SD) = 33.2 (6.4)) in one trial.80 Withdrawal rates were differential in the 
other trial: 4.0% (glargine + OHAs) versus 15.0% (premixed insulin).81 In the latter group, the 
most common reasons for withdrawal were unwillingness to continue (12/28, 42.9%), lack of 
efficacy (5/28, 17.9%), and unspecified (9/28, 32.1%). 
Insulin, as an add-on to existing metformin and sulfonylurea therapy, lowered Ale by 
0.8-1.7% from baseline?6·37·60•80•81 Insulin glargine was the add-on agent in three trials.36•60·81 
Mean doses ranged from 25.0-38.5U/d with reduction in Ale from 1.1-1.7%. NPH insulin was 
the add-on agent in one trial (mean dose 25.8U/d, Ale reduction 0.8%).80 Twice-daily insulin 
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aspart was the add-on agent in the remaining trial (mean dose, 24.4U/d, Ale reduction 0.9%).37 
Three of the trials were designed to test the non-inferiority of other agents, exenatide in two36•37 
and rosiglitazone in the other. 60 Therefore, treatment effects with insulin in these particular trials 
must be interpreted in light of their respective study designs. Still, trial conditions represent 
efficacy more than effectiveness, so the observed effects with insulin should not necessarily be 
taken as the lower range of effects that would be observed in other settings. In two of the trials, 
insulin plus oral hypoglycemics were compared to premixed insulin dosed twice daily as 
monotherapy. 80·81 Reduction in Ale with insulin monotherapy exceeded triple therapy with NPH 
in one study (-!.2% versus -0.8%),80 but was less than triple therapy with glargine in another 
study (-1.31% versus !.64%).81 
From one-fourth to one-half of insulin-treated patients attained Ale levels less than 
7%.36•37•60•80•81 Proportions were consistent among glargine-treated patients (48-49%) in three 
trials36•60•81 and were consistently higher than patients on other insulin-containing regimens, 
whether used in combination or as monotherapy. Some of the difference could be explained by 
the varying use of forced titration, and the aggressiveness or lack thereof, in the trials. 
Better glycemic control and an increased proportion of patients attaining AI c levels less 
than recommended not surprisingly came at the expense of an increased incidence of 
hypoglycemia. One trial performed an additional analysis in which it was revealed that more 
patients reached an A I c<7% without confirmed nocturnal hypoglycemia with glargine ( 46%) 
than with premixed insulin (29%).81 A similar effect (55.2% versus 30.2%) was seen in a planned 
subgroup analysis of the original study conducted in patients >65 years of age (n= 130), reported 
elsewhere. 82 
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gain was more than was observed with exenatide/6•37 but less than with rosiglitazone60 and with 
premixed insulin monotherapy.80·81 Several studies have suggested that metformin, in particular, 
is important for ameliorating the weight gain seen with combination insulin therapy. 
Hypoglycemia was the most common and important side effect. Severe hypoglycemia 
requiring medical assistance was rare. Hypoglycemic events were reported as a rate in all trials 
and ranged from 2.7-7.7 events per patient-year. 36•37•60•80·81 These rates were higher than with 
rosiglitazone, 60 comparable to exenatide, 36•37 and less than observed with premixed insulin 
monotherapy.80•81 Again, incidence of hypoglycemia tends to be related to the study design and 
reflect how insulin is dosed and subsequently titrated. 
None of the trials reported on lipids or on micro- or macro-vascular endpoints. One trial 
reported on cost, and showed a distinct and significant cost advantage for triple therapy with 
once-daily glargine compared to triple therapy with rosiglitazone. 
DISCUSSION 
Summary of findings. Eleven randomized controlled trials, enrolling 3,306 participants 
with a median follow-up duration of24 weeks, were included. Overall, study methodologic 
quality was good. Trial participants were generally similar with respect to age, body mass index 
(BMI), duration of diabetes, and baseline Ale making it possible to generalize the results of this 
review to a likely externally valid population. 
Ale lowering varied from 0.2%-1.8% and from least effective (alpha-glucosidase 
inhibitors) to most effective (thiazolidinediones and insulin glargine). Generalizing these 
averaged results to patients at differing levels of baseline glycemic control is limited. Irrespective 
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of the third agent chosen, less than half of all trial participants attained Ale <7.0%, though this 
may reflect inclusion of participants with advanced disease. Nevertheless, results suggest 
reconsideration of glycemic targets as well as the possible inappropriateness of certain treatment 
recommendations. 
Third agents were generally safe and were well-tolerated. The incidence of serious 
adverse events was low (<3%) including severe hypoglycemia (1.5 events per 100 patient-years). 
Incidence of hypoglycemia appeared related to the sulfonylurea dose, suggesting a treatment 
recommendation, and to the ambient level of glycemic control, suggesting a shifting balance of 
benefits and harms with increasingly intensive therapy. The rarity of serious events precluded 
comparisons among particular agents. 
Few ofthe trials reported on micro- or macro-vascular endpoints, economic 
considerations, or effects on health-related quality of life. The paucity of such data in the 
included literature has implications for future research. 
Efficacy. Interpretation of efficacy measures is confounded by several factors. First, all 
results are reported as population means, irrespective of baseline Ale. Only two studies35•60 
reported an analysis of change in Ale from baseline stratified by baseline Ale. In the trial 
involving exenatide,35 participants whose baseline Ale >9.0% experienced significantly greater 
effects than those whose Ale <9.0% (-1.5% versus -0.5%, respectively). While published 
quantitative results were unavailable for the rosiglitazone versus insulin glargine trial, 60 the 
authors state that when baseline Ale >9.5%, reduction in Ale with insulin glargine was 
significantly greater than with rosiglitazone (in patients with Ale <9.5% there was no significant 
difference between treatment groups). This suggests adding a glitazone may be beneficial when 
baseline Ale is modestly elevated but inappropriate at higher levels. 
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Second, interventions in these trials are initiated at wide-ranging levels of existing 
glycemic control. Typical inclusion criteria admitted participants whose baseline A 1 c was 
between 7.0%-11.0%. Without stratified analysis, the magnitude of Ale lowering is difficult to 
generalize for a patient with an Ale of 8.0% on metformin and sulfonylurea and for another with 
an Ale of 10.0%. Any algorithm predicated on a single treatment recommendation without 
accounting for this is not sufficiently evidence-based. 
Third, unrealized potential exists for these and future studies to clarify whether add-on 
therapy demonstrates a linear relationship or a curvilinear relationship based on baseline A 1 c. If 
diminishing returns are observed irrespective of agent, then shared-decision making-eliciting 
patient values regarding route of administration, likelihood of adverse event, and cost among 
others-should be a highly effective approach. 
Safety. In those trials evaluating hypoglycemia, rates seemed related to two factors. First, 
hypoglycemia seemed to vary with background sulfonylurea dose. In a trial investigating 
exenatide,35 the overall incidence of hypoglycemia was lower among those randomized to a 
minimally effective sulfonylurea dose than those randomized to a maximally tolerated 
sulfonylurea dose (35% versus 21%, respectively) with small attenuation of the effects on 
glycemic control as measured by change in Ale (-0.9% versus -0.6%, respectively). In a second 
trial investigating exenatide,37 33% of exenatide-treated patients had their sulfonylurea dose 
reduced: hypoglycemia rates decreased following sulfonylurea dose reductions from 26.9 events 
per patient year to 6.1 events per patient year with observed reductions in Ale similar between 
those on stable sulfonylurea doses and those on reduced sulfonylurea doses (-0.99% versus-
0.93%, respectively). In the trial investigating rosiglitazone add-on therapy, 59 doses of 
glyburide/metformin were decreased due to hypoglycemia in 18 patients (10.0%), decreasing 
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rates of hypoglycemia without sacrificing efficacy. This suggests a proactive approach to 
sulfonylurea dosing in limiting the incidence of hypoglycemia and has implications for practice. 
Second, hypoglycemia seemed to vary with ambient Ale levels; that is, with increasingly 
tight control, there was an increased incidence of hypoglycemia. In the above-mentioned trial 
investigating rosiglitazone/9 hypoglycemia was associated with lower final Ale levels 
particularly in patients achieving levels <6.5%. This is not a novel finding: the trade-off between 
hypoglycemia and tight control is well-known to clinicians and given this, care should be taken 
with target goals in certain populations such as the elderly and those prone to being 
hypoglycemic unaware among other vulnerable cohorts. 
Implications. While proportion of patients achieving anAl c less than 7.0% was reported 
in many of the studies (8/11, 72.7% ), the proportion of patients achieving this level of control 
was less than half in all studies. It is interesting to note that the treatment goals and measures of 
quality care rely on guidelines and recommendations, though these targets were rarely achieved 
in the trials included in this systematic review. This should not be regarded as failure, though it 
may suggest an inappropriateness of the guidelines. Regardless, it should refocus the discussion 
on the benefits of incremental reductions in Ale, particularly as it relates to risk reduction of 
micro- and macro-vascular endpoints. 
To illustrate the diminishing returns expected to be observed with increasingly intensive 
glycemic control, a hypothetical outcomes table was generated based upon a Markov decision 
model, 83 itself constructed from the Rochester cohort study of diabetic patients and the 
Wisconsin Epidemiologic Study of Diabetic Retinopathy to provide estimates of the rates of 
progression to end-stage outcomes. The table assumes the clinical situation posed in the 
background and rationale section of this review: A fifty-five-year-old, overweight 
(BMI=30kg/m2) adult with long-standing diabetes (10-years post-diagnosis) and an Alc=8.0% 
on maximally-tolerated metformin plus glipizide. 
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The table then inputs the upper limit of demonstrated effectiveness of various third agents 
reviewed herein as well as the proportion of patients experiencing treatment-related adverse 
events. The absolute risk reductions in lifetime risk for blindness due to diabetic retinopathy and 
for end-stage renal disease due to diabetic nephropathy are extrapolated from the model. These 
are then used to calculate the number needed to treat (NNT) to prevent one health outcome-
blindness or end-stage renal disease--as opposed to intermediate outcomes so prevalent in the 
literature. 
While not reflected in the outcomes table, in patients with later onset, moderate glycemic 
control prevents most end-stage complications caused by microvascular disease. Given these 
diminishing returns, the question needs to be reframed away from which agents to choose, given 
relative comparable efficacy (NNT range, 91-333), and toward what target level is appropriate. 
In the same thread, patients with an elevated baseline Ale above a certain threshold may reflect 
advanced disease, diminished beta-cell secretory capacity and increasing peripheral resistance. In 
this instance, it may be inappropriate to recommend an agent other than insulin. 
Cost data was taken from the current Drug Topics 2006 Red Book (October 2006). 
Values listed reflect average wholesale prices where cost for individual subjects was based upon 
the maximum daily dose administered in trials. Calculations do not include the cost oflab 
monitoring, supplies, or increased frequency of self-monitoring of blood glucose levels. They 
also do not comment on whether metformin or sulfonylurea dose might be able to be lowered or 
dropped and the resultant effect on overall cost of treatment. Differences in cost from a health 
systems perspective are important given that improved medical resource utilization resulting 
from better glycemic control may ultimately yield cost-savings. 
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Limitations of the literature. An insufficient trial duration (for purposes of this review, 
less than 24 weeks) was an important exclusion criterion. Despite this, only one trial (the 
UKPDS) had a follow-up period longer than one year and the eleven trials included had a median 
follow-up of 24 weeks. While several agents have reported efficacy past a year, these extended 
trials are open-label and thus introduce important biases into the interpretation of their results. 
Most trials are conducted long enough to demonstrate the effectiveness of the agent, but 
do not address how long that agent is effective. Given that the pathophysiologic defect in type 2 
diabetes mellitus is progressive, the duration of effectiveness-expressed as a period free of 
complications, or the period of time spent above an A 1 cllevel known to place a patient at 
increased risk of complications-is an important consideration in treatment-decisions. Few 
studies, both included and excluded, performed Kaplan-Meier analysis on time to treatment 
failure, however that may be defined, or time to treatment switch (to insulin or to another agent). 
Limitations of this analysis. While information regarding effect on fasting plasma glucose 
and postprandial glucose levels were abstracted when available, this review was not designed to 
address the differential effect of each agent on these two outcomes and the effect that may have 
on glycemic control in general. 
In those trials which performed analyses stratified by baseline Ale, those with higher 
A 1 c at baseline often realized more pronounced reductions in A 1 c. Whether or not this can be 
explained by the mechanistic targeting of fasting and/or postprandial glucose levels and the 
relative contributions of each at varying levels of glycemic control cannot be stated from this 
review. The more poorly controlled the patient is, the more the fasting glucose concentration 
contributes to overall hyperglycemia, whereas in better-controlled patients, postprandial 
glycemia plays a more major role. 84 
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Guidelines on type 2 diabetes conflict with one another about indications for treatment 
and preferred regimens, and most recommendations are based on less than sufficient evidence. 
For example, it is unclear in the case of combination therapy whether sulfonylurea or metformin 
or both should be continued. Studies on insulin posed a formidable challenge as general practice 
and the bulk of the literature is either insulin as monotherapy after oral therapy has failed or 
insulin with either continued metformin or a sulfonylurea after treatment failure with two oral 
agents. 85 This review was again not designed to address the efficacy of any particular regimen or 
to discriminate among them. 86 The constraints of the systematic review were that studies 
regarding insulin would only be admitted if insulin was part of a triple therapy regimen. The 
results of this review are not generalizable to those with higher Ale values many of whom may 
need additional injections of short-acting insulin iflevels of Al c remain above target despite 
optimization of basal insulin. 
This review does not address agents in the drug development pipeline. Limited keyword 
searching suggested no articles would have met inclusion criteria; but, the changing 
armamentarium does curtail the lifespan of any review. However, it does nothing to diminish the 
importance of optimizing treatment decisions informed by rigorous evaluation of the evidence 
and supplemented by shared decision-making between patient and provider. The failure to 
implement already available interventions aggressively and effectively is a major barrier to 
quality care, not remedied by the influx of new medications. 
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Il #60R#70R#80R#90R#l0 
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Table 2. Inclusion and exclusion a 
DRUG CLASS MEDLINE: Articles Articles added by Articles Articles Articles 
references excluded at included at hand-searching of retained rejected included 
identified title/abstract title/abstract bibliographies for full after full 
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INHIBITORS 
GLITAZONES 183 73 10 2 12 9 3 
INSULIN 1184 168 16 10 26 24 2 
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Table 3. Inclusion and exclusion criteria 
CATEGORY INCLUSION 
Study population Adults {>19 years of age inclusive) with 
type 2 diabetes mellitus of any duration 
with an Ale >7.0% on an existing, stable 
regimen of metformin plus a sulfonylurea 
Study setting Outpatient setting (i.e., ambulatory clinics) 
Study design Randomized-controlled trials with follow-
up at least 24 weeks and an evaluable total 
study population of at least thirty 
participants; at least one trial arm must 
include the investigation of an add-on 
third agent to existing dual therapy with 
metforrnin and a placebo; must include an 
active control or placebo though can be 
open label 
Reported outcomes Inclusion of both key outcome measures: 
change in Ale and drug-related adverse 
events or side effects 
EXCLUSION 
Adults with type I diabetes mellitus, 
diabetes of secondary cause, gestational 
diabetes, pre~diabetes, or metabolic 
syndrome; trial conducted in the pediatric or 
adolescent population (<18 years of age 
inclusive) 
Studies conducted in or regarding inpatient, 
hospital, or intensive short-term 
management or comparable settings 
Non-randomized trials, doses of metformin 
and/or sulfonylurea inconsistent with 
clinical practice, inadequate final sample 
size or follow-up period; drugs which have 
been withdrawn from or are not available in 
the US market (i.e., troglitazone) 
Any trial which did not report one or both 
of these key measures 
LIMITS English-language only, research conducted in humans. studies in the published literature 
Table 4. Characteristics of included studies 
DRUG CLASS Agent Existing regimen Randomized ITTpopn Per Age, BMI. Duration, Baseline Duration 
Reference Dosage (met+ sui) popn (n) (nl) protocol mean, SD mean, SD mean, SD Ale(%) offal/ow-
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EXENATIDE 
Kendall DM, Riddle Exenatide MET(> 1500 mg/d) + 241 241 188 55 (10) 34 (6) 8.7 (6.4) 8.5(1.1) 30 
MC, Rosenstock J, et 10ug bid SU (~max, min) 
a/ 
Placebo MET(> 1500 mg/d) + 247 247 184 56 (10) 34 (5) 9.4 (6.2) 8.5 (1.0) 
N/A SU (~max, min) 
Heine RJ, Van Goal I Exenatide MET(~max)+ 283 282 275 59.8 (8.8) 31.4 (4.4) 9.9 (6.0) 8.2 (1.0) 26 
LF, Johns D. eta/ 10ug bid SU (~max) 
Insulin MET(~max) + 268 267 260 58.0 (9.5) 31.3 ( 4.6) 9.2 (5.7) 8.3 (1.0) 
glargine qhs SU (~max) 
(25.0 U/d) 
Nauck MA, Duran S, I Exenatide MET(~max) + 255 253 222 59 (9) 30.6 (4.0) 9.8 (6.3) 8.6 (1.0) 52 
Kim D, eta/ 10ug bid SU (~max) 
Insulin aspart MET(~max) + 250 248 224 58 (9) 30.2 (4.2) 10.0 (6.2) 8.6 (1.1) 
bid (24.4U/d) SU (~max) 
a-GLUCOSIDASE 
INHIBITORS 
Lam KSL, Tiu SC, I Acarbose, MET (x ~ 1790mg/d) + SU 45 45 41 57.8 (1.3) 24.8 (0.5) 10.2 (0.7) 9.5 (0.1) 24 
Tsang MW, et a/ 100mg tid (~max) 
Placebo MET (x ~ 1790 mg/d) + 45 44 40 56.9 (1.3) 24.1 (0.4) 10.1 (0.8) 9.4 (0.1) 
N/A SU (~ax) 
Standi E, I Miglito1, MET (~submax) + 78 78 65 62 (8) 27.7 (3.7) 8 (NR) 8.8 (0.85) 24 
Schernthaner G, 100 mg tid SU (~ submax) 
Rybka J, et a/ 
Placebo MET (~submax) + 76 76 68 61(8) 27.9 (3.5) 9 (NR) 8.8 (0.66) 
N/A SU (~ submax) 
Holman RR, Cull I Acarbose, MET (~submax) + 154 154 59 60 (9) 29.8 (5.6) 7.9 (2.9) 8.7 (NR) 156 
CA, Turner RC 100mg tid SU (~ submax) 
Placebo MET (~submax) + 152 152 73 60 (9) 29.6 (5.7) 8.0 (2.8) 8.7 (NR) 
N/A SU (~ submax) 
GLITAZONES 
Dailey Ill GE, Noor I Rosiglitazone, MET (>l500mg/d) + 181 181 176 57 (9) 32 (5) 9 (7) 8.1 (0.9) 24 
MA, Park JS, eta/ 4mg bid SU (>7.5mg/d) 
Placebo MET(> l500mg/d) + 184 184 179 57 (lO) 32 (5) 9 (6) 8. l (0.8) 
N/A SU (>7.5mg/d) 
Schwartz S, Sievers Pioglitazone MET(~max)+ 90 85 85 54 (9.3) 33 (6.0) 10.4 (6,9) 9.7 (1.6) 24 
R, Strange P, eta/ Rosiglitazone SU (~max) 
Insulin 70/30 MET(~max) 98 98 98 54 (10.8) 34 (5.4) 8.9 (5.7) 9.6 (1.3) 
bid (63Uid) 
Rosenstock J, Rosiglitazone, MET (~2000mg/d) + 113 112 112 55 (11.4) 33.6 (6.3) 8.1 (5.1) 8.7 (l.O) 24 
Sugimoto D, Strange 4mgbid SU (>half-max) 
P, eta/ 
Insulin MET (~2000mg/d) + 106 105 105 56 (10.5) 34.6 (7.0) 8.5 (5.8) 8.8 (l.O) 
glargine SU (>half-max) 
(38.5U/d) 
INSULIN 
Goudswaard A, Insulin 70/30 MET(~max) + 34 31 31 58 (11.3) 28.5 (3.8) 7.7 (4.8) 8.8 ( 1.5) 52 
Stalk R, Zuithoff P, bid SU (~ax) 
eta! (68.3U/d) 
NPHqhs MET(~max)+ 35 33 33 59 (8.6) 33.2 (6.4) 7.2 (3.9) 8.3 (0.9) 
(25.8U/d) SU (~max) 
Janka H, Pi ewe G, I insulin 70/30 MET (x ~ 1895mg/d) + 189 187 187 60.4 (9.1) 29.6 (3.6) 9.9 (6.4) 8.8 (0.9) 24 
Riddle MC, eta/ bid SU (>half-max) 
(64.5U/d) 
Insulin MET (x ~ 1895mg/d) + 182 177 177 60.9 (8.7) 29.5 (3.6) 9.9 (7.3) 8.9 (l.O) 
glargine SU (>half-max) 
(28.2U/d) 
Table 5. Re orted outcomes of included studies 
DRUG CLASS Intervention Change Proportion Hypoglycemia Weight Side effects Lipids Microw Cost data HRQOL 
Reference Comparison in Ale attaining (%or change !macro- orCEA 
(%) Ale< 7% events!. t- r (kf!:! vascular 
EXENATIDE 
Kendall DM, Riddle Exenatide -0.8 34 27.8% -1.6 Nausea (49%), vomiting NR NR NR NR 
MC, Rosenstock J, et (14%), diarrhea (17%) 
a/ Placebo +0.2 9 12.6% -0.9 
Heine RJ, Van Gaal I Exenatide -1.11 46 7.3 e/p-yr -2.3 Nausea (57%), vomiting NR NR NR NR 
LF, Johns D, et al (17%), diarrhea (9%) 
Insulin -1.11 48 6.3 e/p-yr +1.8 
glargine 
Nauck MA, Duran S, I Exenatide -1.04 32 4.7 e/p-yr -2.5 Nausea (33%), vomiting R;NS NR NR NR 
Kim D, eta/ (15%), diarrhea (10%) 
Insulin aspart -0.89 24 5.6 e/p-yr +2.9 
a-GLUCOSIDASE 
INHIBITORS 
Lam KSL, Tiu SC, I Acarbose -0.5 NR R;NS -0.54 Flatulence (62%), R;NS NR NR NR 
Tsang MW, et al diarrhea ( 11%) 
Placebo +0.1 +0.42 
Standi E, Miglitol -0.55 NR R;NS NR Flatulence (30%), R;NS NR NR NR 
Schernthaner G, diarrhea (14%) 
Rybka J, et al Placebo -0.20 
Holman RR, Cull Acarbose, -0.2 NR NR -0.3 Flatulence (30%), NR RR 0.91 NR NR 
CA, Turner RC ITT popn diarrhea (16%) (95%CI: 
Acarbose, PP -0.32 -0.8 0.61-
popn 1.35) 
GLITAZONES I Rosiglitazone Dailey Ill GE, Noor -0.9 42 53% +3.0 Mild-mod edema (8%) R;NS NR NR NR 
MA, Park JS, eta/ 
Placebo +0.1 14 25% +0.03 
Schwartz S, Sievers I Rosiglitazone -1.77 31 48% +3.5 NR NR R; favored NR R; favored NR 
R, Strange P, et al Pioglitazone insulin+met insulin+met 
70/30 bid+ -1.96 32 67% +2.9 
MET 

Table 6. Outcomes table 
For a 55-year-old, overweight (BMI~30kg!m') adult with long-standing diabetes (10-
y:?:.:rs '"VSR!ia"nvsis1 an:! W.111r:=S.0% vn tr.axim::!l••;;tvfrn:.."'r!l! Jr~l'orJPJn nfus n-finfzide 
No additional +Exenatide +a-glucosidase +TZD +Insulin 
therapy inhibitor (basal) 
ABSOLUTE +0.8% -1.0% -0.5% -1.5% -1.7% 
REDUCTION 
HbAlcLEVEL 
NNT(TO NIA ARR=0.8% ARR=0.4% ARR= 1.0% ARR= 1.1% 
PREVENT ONE NNT= 125 NNT=250 NNT= 100 NNT=91 
MICROVASCULAR 
COMPLICATION-
BLINDNESS) 
NNT(TO N/A ARR=0.7% ARR=0.3% ARR= 1.0% ARR=l.l% 
PREVENT ONE NNT= 143 NNT=333 NNT= 100 NNT=91 
MICROVASCULAR 
COMPLICATION-
ESRD) 
LIKELIHOOD OF NIA Nausea Flatulence Mild-mod Severe 
ADVERSE EVENT (33%-57%) (30%-62%) edema hypoglycemia 
Diarrhea :Uiarrhea OS%-13%) {13 events 
(9%-17%) (11%-16%) per 100 
Vomiting patient-years) 
(14%-17%) 
...... ne'T' l<TW ,.,J;.t.;~hu.OI><l TIXe!tiMtltle! Ot A<:ID'tH::i~e Ot "PU: .. atiJ>-:.<...1"""""' :.;: .... GUttgitle ot VV._,! 1 'IV QUUU.lU!UU .r lVl:)!IHlL.UUI::l Ul 
CONSIDERATIONS therapy BYETTA PRECOSE ACTOS LANTUS 
NIA 20ug daily 300mgdaily 45 mgdaily 30U daily 
$0.00/mo $207.00/mo $107.26/mo $195.77/mo $152.29/mo 
Mi&litnl nr Rosiglit~.rone 
-·-<;;>·-·-- --
GLYSET orAVANDIA 
lOOmgdaily 8 mg daily 
$97.36/mo $183.42/mo 
